Psychiatric aspects of the obesity crisis

Psychiatric Times

Volumn 27, Issue 4, 2010, Pages 47-51

  Chiles, Catherine ^a   Van Wattum, Pieter Joost ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952925820     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Ogden CL, Carroll MD, Curtin LR. et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
2. Centers for Disease Control and Prevention. Body mass index. http://www.cdc. gov/healthyweight/assessing/bmi. Accessed February 24, 2010.
3. Devlin MJ, Yanovski SZ, Wilson GT. Obesity: what mental health professionals need to know. Am J Psychiatry. 2000;157:854-866.
4. Pickering RP, Grant BF, Chou SP, Compton WM. Are overweight, obesity, and extreme obesity associated with psychopathology? Results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2007;68:998-1009.
5. Jain A. What works for obesity? April 30, 2004. http:// unrtedhealthfoundation.org/obesitypdf. Accessed February 24, 2010.
6. Zametkin AJ, Zoon CK, Klein HW, Munson S. Psychiatric aspects of child and adolescent obesity: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 2004;43:134-150.
7. McTigue KM, Harris R, Hemphill B, et al. US Department of Health and Human Services. Screening and interventions for obesity in adults: summary of the evidence. http://www.ahrq. gov/clinic/3rduspstf/obesity/obessum.htm. Accessed March 5, 2010.
8. US Preventive Services Task Force, Barton M. Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics. 2010;125:361-367.
9. Paz-Filho G, Esposito K, Hurwitz B, et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am J Physiol Endocrinol Metab. 2008;295: E1401-E1408.
10. Cocores JA, Gold MS. The Salted Food Addiction Hypothesis may explain overeating and the obesity epidemic. Med Hypotheses. 2009;73:892-899.
11. Bjömtorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2:73-86.
12. Chrousos GP. The role of stress and the hypothalamic-pituitaryadrenal axis in the pathogenesis of the metabolic syndrome: neuroendocrine and target tissue-related causes. Int J Obes Relat Metab Disord. 2000;24(suppl 2): S50-S55.
13. Leonard WR. Food for thought Dietary change was a driving force in human evolution. Sci Am. 2002;287:106-115.
14. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat protein, and carbohydrates. N Engl J Med. 2009;360:859-873.
15. Taubes G. Nutrition. The soft science of dietary fat Science. 2001;291:2536-2545.
16. McElroy SL, Hudson JL, Capece JA, et al; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61:1039-1048.
17. Dickerson FB, Brown CH, Kreyenbuhl JA, et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006;113:306-313.
18. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychlatry. 2006;63:824-830.
19. Blaine B. Does depression cause obesity? A meta-analysis of longitudinal studies of depression and weight control. J Health Psychol. 2008;13:1190-1197.
20. van Gemert WG, Severeijns RM, Greve JW, et al. Psychological functioning of morbidly obese patients after surgical treatment. Int J Obes Relat Metab Disord. 1998;22:393-398.
21. Ryan MC, Flanagan S, Kinsella U, et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74:1999-2008.
22. Saami SE, Saami SI, Fogelholm M, et al. Body composition in psychotic disorders: a general population survey. Psychol Med. 2009;39:801-810.
23. Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2008;70:288-297.
24. Atlantis E, Baker M. Obesity effects on depression: systematic review of epidemiological studies. Int J Obes (bond). 2008;32:881-891.
25. Tanofsky-Kraff M, Wilfley DE, Spurrell E. Impact of interpersonal and ego-related stress on restrained eaters. Int J Eat Disord. 2000;27:411-418.
26. Slochower J. The psychodynamics of obesity: a review. Psychoanal Psychol. 1987;4:145-159.
27. Greeno CG, Wing RR. Stress-induced eating. Psychol Bull. 1994;115:444-464.
28. Roemmich JN, Wright SM, Epstein LH. Dietary restraint and stressinduced snacking in youth. Obes Res. 2002;10:1120-1126.
29. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents [published correction appears in JAMA 2009;302:2322].
30. JAMA 2009;302:1765-1773.
31. Mclntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med. 2008;162:929-935.
32. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
33. National Heart, Lung, and Blood Institute; American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. 2000. http://www.nhlbi. nih. gov/guidelines/obesity/prctgd-cpdf. Accessed February 24, 2010.
34. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67:17-24.
35. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
36. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(suppl 1): S11-S61.
37. Alvarez-Jiménez M, Hetrick SE, González-Blanch C, et al. Nonpharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101-107.
38. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RL. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand. 2007;115:286-294.
39. Kalarchian MA, Marcus MD, Levine MD, et al. Behavioral treatment of obesity in patients taking antipsychotic medications. J Clin Psychiatry. 2005;66:1058-1063.
40. Richardson DW, Vlnik AL. Metabolic implications of obesity: before and after gastric bypass. Gastroenterol Clin North Am. 2005;34:9-24.
41. Meridia (sibutramine) [package insert]. North Chicago, IL: Abbott; 2010.
42. Xenical (oriistat) [package insert]. Sydney, Australia: Roche; 2005.
43. Phentermine [package insert]. Totowa, NJ: Actavis; 2006.
44. James W P T. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl. 2005;7(suppl 1): L44-L48.
45. Miller LJ. Management of atypical antipsychotic drug-induced weight gain: focus on metformin. Pharmacotherapy. 2009;29:725-735.
46. Shin L, Bregman H, Breeze JL, et al. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol. 2009;19:275-279.
47. Baptista T, Uzcátegui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res. 2008;159:250-253.
48. Egger C, Muehlbacher M, Schatz M, Nickel M. Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. J Clin Psychopharmacol. 2007;27:475-478.
49. Smith ME, Gevins A, McEvoy LK, et al. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia. 2006;47:695-703.
50. Kockelmann E, Elger CE, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res. 2003;54:171-178.
51. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17:30-39.
52. Masaki T, Yoshimatsu H. Neuronal histamine and its receptors in obesity and diabetes. Curr Diabetes Rev. 2007;3:212-216. (Pubitemid 47244067)
53. 3, antagonist on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005;20:101-103.
54. Pittier MH, Schmidt K, Ernst E. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev. 2005;6:93-111.
55. Pittier MH, Ernst E. Complementary therapies for reducing body weight: a systematic review. Int J Obes (bond). 2005;29:1030-1038. (Pubitemid 41192209)
56. Kalarchian MA, Marcus MD, Levine MD, et al. Psychiatric disorders among bariatric surgery candidates: relationship to obesity and functional health status. Am J Psychiatry. 2007;164:328-334.
57. Dimick JB, Welch HG, Birkmeyer JD. Surgical mortality as an indicator of hospital quality: the problem with small sample size. JAMA 2004;292:847-851.
58. Schneider BE, Mun EC. Surgical management of morbid obesity. Diabetes Care. 2005;28:475-480.
59. Masheb RM, White MA, Toth CM, et al. The prognostic significance of depressive symptoms for predicting quality of life 12 months after gastric bypass. Compr Psychiatry. 2007;48:231-236.
60. Buddeberg-Fischer B, Klaghofer R, Krug L, et al. Physical and psychosocial outcome in morbidly obese patients with and without bariatric surgery: a 41/2-year follow-up. Obes Surg. 2006;16:321-330.
61. Pull CB. Current psychological assessment practices in obesity surgery programs: what to assess and why. Curr Opin Psychiatry. 2010;23:30-36.
62. Scholtz S, Bidlake L, Morgan J, et al. Long-term outcomes following laparoscopic adjustable gastric banding: postoperative psychological sequelae predict outcome at 5-year follow-up. Obes Surg. 2007;17:1220-1225.
63. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: US Dept of Health and Human Services. Agency for Healthcare Research and Quality. May 2008.